"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04276987","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia",,"Completed","No Results Available","Coronavirus","Biological: MSCs-derived exosomes","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXCOVID","February 15, 2020","May 31, 2020","July 31, 2020","February 19, 2020",,"September 7, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04276987"
2,"NCT05060107","Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)","ExoOA-1","Not yet recruiting","No Results Available","Osteoarthritis, Knee","Biological: Exosomes (sEVs)","Adverse Event|Incidence of injection-related pain according to VAS scale (0-100mm)|Incidence of injection-related sinovitis according to effusion grading scale of knee joint|Pain reduction|Disability reduction|Percentage of responders","Francisco Espinoza|Universidad de los Andes, Chile","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C4C060921","October 5, 2021","April 5, 2023","October 5, 2023","September 28, 2021",,"September 28, 2021",,,"https://ClinicalTrials.gov/show/NCT05060107"
3,"NCT03608631","iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation",,"Recruiting","No Results Available","KRAS NP_004976.2:p.G12D|Metastatic Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8","Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA","Maximum Tolerated Dose Determined by Dose Limiting Toxicity|Minimal residual disease rate in high-risk patients|Overall survival (OS)|Progression-free survival (PFS)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0126|NCI-2018-01441","January 27, 2021","March 31, 2022","March 31, 2022","August 1, 2018",,"April 29, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03608631"
4,"NCT04313647","A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers",,"Completed","Has Results","Healthy","Biological: 1X level of MSCs-Exo|Biological: 2X level of MSCs-Exo|Biological: 4X level of MSCs-Exo|Biological: 6X level of MSCs-Exo|Biological: 8X level of MSCs-Exo","Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE)","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXVT","March 12, 2020","April 30, 2020","July 31, 2020","March 18, 2020","August 4, 2021","August 4, 2021","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04313647"
